A Dose Escalation Study of ASP8273 in Subjects With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations

NCT02113813 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

133

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Small-Cell Lung Cancer (NSCLC)
Epidermal Growth Factor Receptor Mutations

Interventions

DRUG: naquotinib
DRUG: midazolam

Sponsor

Astellas Pharma Global Development, Inc.